These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

428 related items for PubMed ID: 27171754

  • 1. Pneumococcal conjugate vaccine herd effects on non-invasive pneumococcal pneumonia in elderly.
    van Werkhoven CH, Hollingsworth RC, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Sanders EA, Bonten MJ.
    Vaccine; 2016 Jun 14; 34(28):3275-82. PubMed ID: 27171754
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
    Ben-Shimol S, Givon-Lavi N, Grisaru-Soen G, Megged O, Greenberg D, Dagan R, Israel Bacteremia and Meningitis Active Surveillance Group.
    Vaccine; 2018 Aug 28; 36(36):5477-5484. PubMed ID: 28579230
    [Abstract] [Full Text] [Related]

  • 4. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay.
    Pletz MW, Ewig S, Rohde G, Schuette H, Rupp J, Welte T, Suttorp N, Forstner C, CAPNETZ Study Group.
    Vaccine; 2016 Apr 29; 34(20):2342-8. PubMed ID: 27016653
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
    Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Miron D, Aviner S, Dagan R, Israel Bacteremia and Meningitis Active Surveillance Group.
    Vaccine; 2016 Aug 31; 34(38):4543-4550. PubMed ID: 27475471
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.
    Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.
    Clin Ther; 2013 Feb 31; 35(2):119-34. PubMed ID: 23312274
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
    Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.
    Vaccine; 2013 Dec 16; 31(52):6232-8. PubMed ID: 24176490
    [Abstract] [Full Text] [Related]

  • 12. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults.
    Chalmers JD, Campling J, Dicker A, Woodhead M, Madhava H.
    BMC Pulm Med; 2016 May 11; 16(1):77. PubMed ID: 27169895
    [Abstract] [Full Text] [Related]

  • 13. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
    van Werkhoven CH, Bonten MJ.
    Future Microbiol; 2015 May 11; 10(9):1405-13. PubMed ID: 26347153
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.
    García Gabarrot G, López Vega M, Pérez Giffoni G, Hernández S, Cardinal P, Félix V, Gabastou JM, Camou T, Uruguayan SIREVA II Group.
    PLoS One; 2014 May 11; 9(11):e112337. PubMed ID: 25375647
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of a 3 + 0 pneumococcal conjugate vaccine schedule against invasive pneumococcal disease among a birth cohort of 1.4 million children in Australia.
    Gidding HF, McCallum L, Fathima P, Moore HC, Snelling TL, Blyth CC, Jayasinghe S, Giele C, de Klerk N, Andrews RM, McIntyre PB, ACIR linkage Investigator Team.
    Vaccine; 2018 May 03; 36(19):2650-2656. PubMed ID: 29627233
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Streptococcus pneumoniae serotype 3 is masking PCV13-mediated herd immunity in Canadian adults hospitalized with community acquired pneumonia: A study from the Serious Outcomes Surveillance (SOS) Network of the Canadian immunization research Network (CIRN).
    LeBlanc JJ, ElSherif M, Ye L, MacKinnon-Cameron D, Ambrose A, Hatchette TF, Lang ALS, Gillis HD, Martin I, Demczuk W, Andrew MK, Boivin G, Bowie W, Green K, Johnstone J, Loeb M, McCarthy AE, McGeer A, Semret M, Trottier S, Valiquette L, Webster D, McNeil SA.
    Vaccine; 2019 Aug 23; 37(36):5466-5473. PubMed ID: 31345638
    [Abstract] [Full Text] [Related]

  • 19. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
    Regev-Yochay G, Katzir M, Strahilevitz J, Rahav G, Finn T, Miron D, Maor Y, Chazan B, Schindler Y, Dagan R, IAIPD group.
    Vaccine; 2017 Apr 25; 35(18):2449-2456. PubMed ID: 28342668
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.